NCT04306913

Outcome of Esmolol Potassium Cardioplegia Compared to Potassium Cardioplegia in Patients With Solitary Valvular Disease; Randomized Controlled Study

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Kasr El Aini Hospital · Academic / Other
• Sex: All
• Age: 20 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

Perioperative myocardial injury remains one of the most serious complications of cardiac surgery. Numerous factors have been implicated during the pathogenesis process, including the technique of cardiac surgery, induction of cardioplegia and period of cardiac arrest. Lactic acid is the normal endpoint of the anaerobic breakdown of glucose in the tissues. The lactate exits the cells and is transported to the liver, thus it's considered to be an indicator of ischemia as it is produced by most tissues in the human body, with the highest level of production found in muscle. In any cardiac valve replacement surgery, patient must undergo cardiac bypass and arrest in diastole by using hyperkalemic cardioplegia solution; meanwhile the metabolism of myocardial cells is purely anaerobic. Esmolol an ultra-short beta blocker is supposed to decrease the anaerobic insult to the myocardial cells.

Conditions

• Cardioplegia Solution Adverse Reaction

Interventions

Type	Name	Description
DRUG	Esmolol	esmolol 250 mg in cardioplegia solution every 25 minutes
DRUG	Potassium Cardioplegic Solution	15 meq potassium added to cardioplegia solution

Timeline

• Start date: 2020-04-01
• Primary completion: 2020-09-01
• Completion: 2020-09-01
• First posted: 2020-03-13
• Last updated: 2020-03-13

Locations

1 site across 1 country: Egypt